# First technical assessment

> **Enquiry:** We read the supplied LED NIR kidney study and want to use the same concept to guide tumor boundary decisions during live surgery. Can we quote its findings as proof that the proposed sensor is ready for that use? We have no new in vivo data and no validation on our own setup. What assessment and next feasibility steps are appropriate?

**Quality checks:** 12/16 · **Sourced claims verified:** 5/8 · **Unsupported numbers:** 0

## 01. Decision Status
**Outside the supported scope** · **Confidence:** insufficient (computed, not self-reported)

The LED NIR kidney study is an in vitro proof of concept and cannot be quoted as proof that the sensor is ready for live surgical decision-making; clinical validation and regulatory work are required.

**Problems found in the request**
- Clinical or in vivo use is outside the supported evidence: The supplied clinical evidence is an in vitro proof of concept (two LED NIR prototypes, 14 in vitro samples from 7 patients) and model-tissue lab work. It cannot be quoted as proof that a sensor is ready to guide decisions in live surgery; that use is outside the supported scope and would need clinical validation and regulatory work beyond this assessment. [S03 p.1, S03 p.14, S04 p.1]

**The customer's own claims, tested first**
- **contradicted**: "LED NIR kidney study demonstrates sensor readiness for tumor boundary decisions during live surgery.". The study is an in vitro proof‑of‑concept with only 14 samples and no in‑vivo data; it cannot be quoted as proof that the sensor is ready for live surgical decision‑making. [S03 p.1] [S03 p.14]
- **contradicted**: "Can we quote its findings as proof that the proposed sensor is ready for that use?". Rule R_CLINICAL_SCOPE states that the in vitro evidence cannot be used as proof of readiness for live surgery; regulatory and clinical validation are required. [S03 p.1] [S03 p.14]
- **partly supported**: "What assessment and next feasibility steps are appropriate?". The evidence supports that further validation is needed: improve LED number/wavelength, optimize measurement conditions, and perform in‑vivo testing with real surgical samples before clinical use. [S03 p.13] [S03 p.13]

To raise confidence, answer: What is the sample (liquid, powder, melt, tissue...) and its main components? / Is the sample clear, turbid or opaque, and does this change during the process? / What concentration range must be covered, and what is the smallest change that matters?

## 02. Requirements stated
- Client wants to use LED NIR kidney study to justify sensor for tumor boundary during live surgery.
- Client lacks new in vivo data or validation on their setup.
- Client asks if findings can be quoted as proof and what assessment/feasibility steps are needed.

## 03. Key unknowns
- Whether the study’s findings are directly applicable to the specific surgical environment.
- Specific sensor hardware and calibration used in the study.
- Patient population and tumor types in the study.

## 04. Clarification questions
1. **What is the specific clinical endpoint and acceptance criteria for 'tumor boundary decisions' (e.g., margin clearance, real-time classification accuracy) that the sensor must meet?** _(high impact)_. Why: The current study is an in vitro proof of concept; defining the clinical target is required to determine the scope of necessary validation and regulatory pathway.
2. **Do you have access to a representative set of ex vivo tissue samples (healthy and tumor) from the relevant organ and tumor types to build a validation dataset?** _(high impact)_. Why: The study notes limited sample availability (14 samples from 7 patients); a robust clinical validation requires a larger, representative dataset to avoid overfitting and ensure generalizability.
3. **What are the specific hardware constraints and measurement conditions (distance, angle, light intensity) in your intended surgical environment?** _(medium impact)_. Why: The study identifies optimization of measurement conditions as a key area for improvement; understanding the operational context is necessary to assess feasibility and required sensor modifications.
4. **Is there a plan for regulatory engagement (e.g., FDA, CE marking) and clinical trial design to support the transition from proof of concept to clinical use?** _(medium impact)_. Why: Clinical decision support requires regulatory approval; understanding the current stage of regulatory planning helps in structuring the next feasibility steps.
5. **Are there existing in vivo data or pilot studies from other groups that could be used to inform the sensor design or validation strategy?** _(low impact)_. Why: While the current study is in vitro, leveraging existing in vivo data could help refine the sensor design and reduce the risk of failure in later clinical trials.

## 05. Recommendation

### NIR (LED-based sensor) (primary)
- The study demonstrates the feasibility of an LED-based NIR sensor for tumor detection in an in vitro setting. [S03 p.1] _(sourced)_
- The study identifies the need to improve the accuracy and specificity of detection for clinical use. [S03 p.14] _(sourced ⚠ scope warning)_
- Optimize the LED number, wavelength, and measurement conditions to reduce measurement variance and improve sensor performance. _(proposal)_
- _Applies if:_ Only if a representative set of ex vivo tissue samples and a defined clinical endpoint are available.

**Method screening (deterministic, from sourced rules)**

| Method | Score | Verdict |
|---|---|---|
| NIR spectroscopy | 0 | weak |
| MIR spectroscopy (ATR) | 0 | weak |
| Raman spectroscopy | 0 | weak |
| UV/Vis spectroscopy | 0 | weak |
| Fluorescence spectroscopy | 0 | weak |

## 06. Measurement concept
- The study used two LED-based NIR sensor prototypes with 14 in vitro clinical samples from 7 patients, showing high measurement variance in cancer tissue samples. [S03 p.1] [S03 p.14] _(sourced ⚠ scope warning)_
- The study identifies the need to improve the accuracy and specificity of detection, as false negatives are unacceptable in oncological diagnostics. [S03 p.14] _(sourced)_
- Optimize the LED number, wavelength, and measurement conditions (distance, angle, light intensity) to reduce measurement variance and improve sensor performance. _(proposal)_

## 07. Spectral range
- NIR light penetrates into the sample by up to 3 mm, which is advantageous for tissue diagnostics. [S03 p.2] _(sourced)_
- The study used four LEDs with emission wavelengths in the NIR range. [S03 p.14] _(sourced)_

## 08. Risks and uncertainty
- The current sensor prototype has high measurement variance in cancer tissue samples, which could lead to false negatives in clinical use. [S03 p.14] _(sourced ⚠ scope warning)_
- The study is based on a very limited number of patients (7), which may not be representative of the broader patient population. [S03 p.6] _(sourced)_
- The sensor's performance in a live surgical environment may differ from the in vitro conditions due to factors such as tissue movement, blood presence, and environmental effects. _(assumption)_
- Regulatory approval for clinical use will require extensive clinical validation and may take several years. _(assumption)_

**Confidence: insufficient**
- Information: insufficient (0/10 decision-relevant facts known; target defined: partial)
- Evidence: insufficient (Only general method knowledge applies; no direct application example in the sources)
- Scope fit: insufficient (Requested use (clinical/in vivo) exceeds the in-vitro / lab scope of the evidence)
- Client premises: low (2 contradicted, 0 unverifiable, 1 supported)
- Verification: low (5/8 sourced claims verified; 0 unsupported numbers)
- Model agreement: low (1/2 drafts share the lead method(s) none; 2/2 share the status 'outside_supported_scope' (2 model families))
- Cap: R_CLINICAL_SCOPE: cap insufficient
- Cap: R_CERTAINTY_DEMAND: cap low

## 09. Decision basis
- Client-agreed acceptance criteria for tumor boundary classification accuracy and specificity on independent ex vivo tissue samples.
- Demonstration of reduced measurement variance compared to the current prototype.
- Successful optimization of LED number, wavelength, and measurement conditions to improve sensor performance.

## 10. Sources
- **S03 p.1**: Development and Testing of an LED-Based Near-Infrared Sensor for Human Kidney Tumor Diagnostics (Sensors 2017) _(proof_of_concept_in_vitro)_
  - "Two sensor prototypes were tested using 14 in vitro clinical samples of 7 different patients."
  - "the present prototype should be further improved, the results reported here can be considered as a successful feasibility study of an LED-based NIR sensor for cancer diagnostics aimed at in vivo applications."
- **S03 p.2**: Development and Testing of an LED-Based Near-Infrared Sensor for Human Kidney Tumor Diagnostics (Sensors 2017) _(proof_of_concept_in_vitro)_
  - "It is important that the NIR light penetrates into the sample by up to 3 mm [20,21]; this depth cannot be reached by suitable spectroscopic techniques in other wavelength regions."
- **S03 p.6**: Development and Testing of an LED-Based Near-Infrared Sensor for Human Kidney Tumor Diagnostics (Sensors 2017) _(proof_of_concept_in_vitro)_
  - "conclusions about the general suitability of the NIR sensor analysis for cancer diagnostics and, in particular, of four theoretically chosen LEDs are made on the basis of a very limited number of investigated patients."
- **S03 p.13**: Development and Testing of an LED-Based Near-Infrared Sensor for Human Kidney Tumor Diagnostics (Sensors 2017) _(proof_of_concept_in_vitro)_
  - "The main requirement for the sensor improvement is therefore to increase the accuracy and specificity of detection, as FN are unacceptable outcomes in oncological diagnostics."
  - "The directions for the further improvement of the sensor are (1) LED number and wavelength optimization, (2) optimization of the measurement conditions (distance, angle, light intensity, spectral reference, probe construction, elimination of environmental effects, etc.), and (3) data processing optimization."
- **S03 p.14**: Development and Testing of an LED-Based Near-Infrared Sensor for Human Kidney Tumor Diagnostics (Sensors 2017) _(proof_of_concept_in_vitro)_
  - "The main requirement for the sensor improvement is therefore to increase the accuracy and specificity of detection, as FN are unacceptable outcomes in oncological diagnostics." ⚠ scope_warning
  - "The main disadvantage of the LED-based sensor in its present form is a very high measurement variance in cancer tissue samples (Figure 9)." ⚠ scope_warning
  - "Only four LEDs with emission wavelengths in the NIR range were employed."
  - "The sensor’s general sensitivity to the kidney tumors, illustrated here, provides the necessary motivation for further development of the method."

**Verifier warnings**
- recommendations[0].rationale[1]: scope_warning S03 is in-vitro proof of concept; it cannot support a readiness claim
- measurement_concept[0]: scope_warning S03 is in-vitro proof of concept; it cannot support a readiness claim
- risks[0]: scope_warning S03 is in-vitro proof of concept; it cannot support a readiness claim

## 11. First feasibility experiment
**Samples**
- Representative ex vivo tissue samples (healthy and tumor) from the relevant organ and tumor types, including physical variation (e.g., tissue density, moisture content).
**Reference measurements**
- Independent reference measurements using histopathology (gold standard) on the same ex vivo tissue samples.
- Comparison with full-range NIR spectroscopy results on the same samples to validate the LED-based approach.
**Comparison**
- Compare the performance of the current LED-based sensor against a full-range NIR spectrometer on the same ex vivo tissue samples.
- Evaluate the impact of varying the number of LEDs and their wavelengths on the sensor's accuracy and specificity.
- Assess the robustness of the sensor under different measurement conditions (distance, angle, light intensity) to simulate real-world surgical variability.
**Steps**
1. Define the clinical endpoint and acceptance criteria for tumor boundary decisions.
2. Collect a representative set of ex vivo tissue samples (healthy and tumor) from the relevant organ and tumor types.
3. Optimize the LED number, wavelength, and measurement conditions (distance, angle, light intensity) to improve sensor accuracy and specificity.
4. Validate the optimized sensor on the ex vivo tissue samples using histopathology as the reference standard.
5. Assess the robustness of the sensor under different measurement conditions to simulate real-world surgical variability.
6. Prepare a regulatory submission plan for clinical validation and regulatory approval.

**Next step with AFS**
- Define the clinical endpoint and acceptance criteria, and collect a representative set of ex vivo tissue samples for sensor optimization and validation.
- Likely path: undecided - Too early: the target or the scope must be settled first.
- Path A (chosen by the expert): **premature**. Clinical decision support needs clinical validation before any routine model. [S03 p.1, S03 p.14]
- Path B (chosen by the expert): **premature**. A lab system can support further ex vivo research, but not the requested clinical use. [S03 p.1, S03 p.14]
- Path C (chosen by the expert): **premature**. The LED sensor is an in vitro proof of concept; a sensor for clinical decisions needs clinical validation first. [S03 p.1, S03 p.14]

**If you proceed anyway with Path A** (Path A (chemometric model for process automation) is premature here: Clinical decision support needs clinical validation before any routine model.)
1. Collect representative samples across the client-agreed range, each with an independent reference value.
2. Record full spectra with the short-listed method(s) and build a calibration model; validate it on held-out batches or runs.
3. Agree how the model is maintained (recalibration triggers, matrix changes) before it is used for process control.
_Sources: S01 p.5, S02 p.20_

**If you proceed anyway with Path B** (Path B (customised multi-spectral system for R&D) is premature here: A lab system can support further ex vivo research, but not the requested clinical use.)
1. Specify the lab kit from the methods short-listed in this assessment: spectrometers, fiber probes, software.
2. Run the method comparison on the customer's own samples in their lab.
3. Use the results as the basis for a later process solution (Path A or C).
_Sources: S02 p.20, S01 p.4_

**If you proceed anyway with Path C** (Path C (customised spectral IoT sensor) is premature here: The LED sensor is an in vitro proof of concept; a sensor for clinical decisions needs clinical validation first.)
1. Run a lab trial with full-spectrum instruments on representative samples.
2. Select the most informative wavelengths and check that a few-band model reaches the client-agreed error on independent samples.
3. Build and test a prototype LED / filter sensor against the reference method before any volume order.
_Sources: S01 p.9, S03 p.14, S02 p.18_

**Proposed setup** (ranked by recommendation; validate in a lab trial)

| System | Path A: Chemometric model for process automation | Path B: Multi-spectral system for your R&D lab | Path C: Low-cost spectral sensors |
|---|---|---|---|
| 1. NIR (LED-based sensor) (primary) | Models: Target calibration → Process predictions | Lab system: NIR measurement channel, Sample / probe, Acquisition + reference data → Spectra + reference values | Sensor system: NIR sensor, Process probe(s), Acquisition + control interface → Process monitoring |

## Council
Winner: draft B; agreement 50% (1/2 drafts share the lead method(s) none; 2/2 share the status 'outside_supported_scope')
- Draft A (openai/gpt-oss-120b): judge score 4.83, gate failures: G2 No unsupported numbers, G4 Evidence used within its scope
- Draft B (qwen/qwen3.8-27b): judge score 5.0, gate failures: G1 Sourced claims verified on the cited page, G4 Evidence used within its scope, H1 No guarantee or readiness wording
- Draft C (openai/gpt-oss-20b): judge score 0.0, gate failures: none

_Generated by the AFS assessment assistant (run 36f004eb50, mode council, server default models; models used: openai/gpt-oss-120b, openai/gpt-oss-20b, qwen/qwen3.8-27b)._

---

# Appendix: how this assessment was made

Contents: A Path analysis · B Extracted requirements · C Rules that fired · D Method screening · E Spectral coverage · F Evidence retrieved · G Verification · H Quality checks · I Confidence · J Enquiry coach · K Council · L What-if changes · M Retrieval and model trace

## A. AFS path analysis
**Suggested path:** undecided. Too early: the target or the scope must be settled first. [-]

| Path | Requested by | Verdict | Reason | Sources |
|---|---|---|---|---|
| A | expert | premature | Clinical decision support needs clinical validation before any routine model. | S03 p.1, S03 p.14 |
| B | expert | premature | A lab system can support further ex vivo research, but not the requested clinical use. | S03 p.1, S03 p.14 |
| C | expert | premature | The LED sensor is an in vitro proof of concept; a sensor for clinical decisions needs clinical validation first. | S03 p.1, S03 p.14 |

## B. Extracted requirements
**Summary:** Client wants to use LED NIR kidney study to justify sensor for tumor boundary during live surgery, but lacks new in vivo data or validation on their setup. They ask if findings can be quoted as proof and what assessment/feasibility steps are needed.

| Field | Value |
|---|---|
| target variables | - |
| target defined | partial |
| matrix | unknown |
| phase | unknown |
| optical behavior | unknown |
| aqueous | unknown |
| fluorescent target | unknown |
| heterogeneous | unknown |
| temperature | unknown |
| fouling risk | unknown |
| process context | clinical |
| analyzer remote | unknown |
| link length known | no |
| existing assets | LED NIR kidney study |
| requested methods | NIR |
| reference method | unknown |
| concentration level | unknown |
| measurement points | unknown |
| preferred paths | - |

**Facts** (stated / inferred, with the words they come from)
- study_type: LED NIR kidney study _(stated)_ — "LED NIR kidney study"
- application: tumor boundary decisions during live surgery _(stated)_ — "tumor boundary decisions during live surgery"
- validation_status: no new in vivo data and no validation on our own setup _(stated)_ — "no new in vivo data and no validation on our own setup"

**Unknowns**
- whether the study’s findings are directly applicable to their specific surgical environment _(high impact)_: Could change feasibility assessment
- specific sensor hardware and calibration used in the study _(high impact)_: Needed to assess compatibility
- patient population and tumor types in the study _(medium impact)_: Affects generalizability

**Client premises found**
- P1 (method claim): "LED NIR kidney study demonstrates sensor readiness for tumor boundary decisions during live surgery."
- P2 (certainty request): "Can we quote its findings as proof that the proposed sensor is ready for that use?"
- P3 (other): "What assessment and next feasibility steps are appropriate?"

## C. Rules that fired (4)
| Severity | Rule | Finding | Sources |
|---|---|---|---|
| block | R_CLINICAL_SCOPE: Clinical or in vivo use is outside the supported evidence | The supplied clinical evidence is an in vitro proof of concept (two LED NIR prototypes, 14 in vitro samples from 7 patients) and model-tissue lab work. It cannot be quoted as proof that a sensor is ready to guide decisions in live surgery; that use is outside the supported scope and would need clinical validation and regulatory work beyond this assessment. | S03 p.1, S03 p.14, S04 p.1 |
| warn | R_CERTAINTY_DEMAND: Request for a final configuration on missing facts | An exact configuration cannot be justified before the target, sample optics, conditions and acceptance criteria are known; method selection depends on many factors and is decided by comparison on real samples. | S01 p.5, S02 p.3 |
| info | R_NO_REFERENCE: Reference method unknown | - | S01 p.5, S01 p.10 |
| info | R_PATH_MANY_LOW_COST_POINTS: Many measuring points at low cost favour spectral sensors | - | S02 p.18, S02 p.19 |

## D. Method screening (deterministic)
| Method | Score | Verdict | Asked for by client | Contributions |
|---|---|---|---|---|
| NIR spectroscopy | 0 | weak | yes | - |
| MIR spectroscopy (ATR) | 0 | weak | no | - |
| Raman spectroscopy | 0 | weak | no | - |
| UV/Vis spectroscopy | 0 | weak | no | - |
| Fluorescence spectroscopy | 0 | weak | no | - |

## E. Spectral coverage (method range vs fiber transmission)
| Method | Method range | Fiber | Fiber range | Overlap | Covers |
|---|---|---|---|---|---|
| NIR | 0.78-2.5 µm | UV-VIS silica fiber (standard or Al/Cu-coated) | 0.18-1.2 µm | 0.78-1.2 µm | partial |
| NIR | 0.78-2.5 µm | VIS-NIR silica fiber (standard or Al/Cu-coated) | 0.35-2.4 µm | 0.78-2.4 µm | partial |
| NIR | 0.78-2.5 µm | Chalcogenide As-S IR fiber (CIR) | 1.1-6.5 µm | 1.1-2.5 µm | partial |
| NIR | 0.78-2.5 µm | Polycrystalline silver-halide IR fiber (PIR) | 3-17 µm | - | none |
| NIR | 0.78-2.5 µm | Hollow glass waveguide | 2-18 µm | 2-2.5 µm | partial |
| NIR | 0.78-2.5 µm | Indium fluoride fiber | 0.3-5.5 µm | 0.78-2.5 µm | full |
| NIR | 0.78-2.5 µm | Zirconium fluoride fiber | 0.3-4.5 µm | 0.78-2.5 µm | full |
| MIR | 2.5-25 µm | UV-VIS silica fiber (standard or Al/Cu-coated) | 0.18-1.2 µm | - | none |
| MIR | 2.5-25 µm | VIS-NIR silica fiber (standard or Al/Cu-coated) | 0.35-2.4 µm | - | none |
| MIR | 2.5-25 µm | Chalcogenide As-S IR fiber (CIR) | 1.1-6.5 µm | 2.5-6.5 µm | partial |
| MIR | 2.5-25 µm | Polycrystalline silver-halide IR fiber (PIR) | 3-17 µm | 3-17 µm | partial |
| MIR | 2.5-25 µm | Hollow glass waveguide | 2-18 µm | 2.5-18 µm | partial |
| MIR | 2.5-25 µm | Indium fluoride fiber | 0.3-5.5 µm | 2.5-5.5 µm | partial |
| MIR | 2.5-25 µm | Zirconium fluoride fiber | 0.3-4.5 µm | 2.5-4.5 µm | partial |
| RAMAN | 0.4-1.1 µm | UV-VIS silica fiber (standard or Al/Cu-coated) | 0.18-1.2 µm | 0.4-1.1 µm | full |
| RAMAN | 0.4-1.1 µm | VIS-NIR silica fiber (standard or Al/Cu-coated) | 0.35-2.4 µm | 0.4-1.1 µm | full |
| RAMAN | 0.4-1.1 µm | Chalcogenide As-S IR fiber (CIR) | 1.1-6.5 µm | - | none |
| RAMAN | 0.4-1.1 µm | Polycrystalline silver-halide IR fiber (PIR) | 3-17 µm | - | none |
| RAMAN | 0.4-1.1 µm | Hollow glass waveguide | 2-18 µm | - | none |
| RAMAN | 0.4-1.1 µm | Indium fluoride fiber | 0.3-5.5 µm | 0.4-1.1 µm | full |
| RAMAN | 0.4-1.1 µm | Zirconium fluoride fiber | 0.3-4.5 µm | 0.4-1.1 µm | full |
| UVVIS | 0.19-0.74 µm | UV-VIS silica fiber (standard or Al/Cu-coated) | 0.18-1.2 µm | 0.19-0.74 µm | full |
| UVVIS | 0.19-0.74 µm | VIS-NIR silica fiber (standard or Al/Cu-coated) | 0.35-2.4 µm | 0.35-0.74 µm | partial |
| UVVIS | 0.19-0.74 µm | Chalcogenide As-S IR fiber (CIR) | 1.1-6.5 µm | - | none |
| UVVIS | 0.19-0.74 µm | Polycrystalline silver-halide IR fiber (PIR) | 3-17 µm | - | none |
| UVVIS | 0.19-0.74 µm | Hollow glass waveguide | 2-18 µm | - | none |
| UVVIS | 0.19-0.74 µm | Indium fluoride fiber | 0.3-5.5 µm | 0.3-0.74 µm | partial |
| UVVIS | 0.19-0.74 µm | Zirconium fluoride fiber | 0.3-4.5 µm | 0.3-0.74 µm | partial |
| FLUO | 0.25-0.8 µm | UV-VIS silica fiber (standard or Al/Cu-coated) | 0.18-1.2 µm | 0.25-0.8 µm | full |
| FLUO | 0.25-0.8 µm | VIS-NIR silica fiber (standard or Al/Cu-coated) | 0.35-2.4 µm | 0.35-0.8 µm | partial |
| FLUO | 0.25-0.8 µm | Chalcogenide As-S IR fiber (CIR) | 1.1-6.5 µm | - | none |
| FLUO | 0.25-0.8 µm | Polycrystalline silver-halide IR fiber (PIR) | 3-17 µm | - | none |
| FLUO | 0.25-0.8 µm | Hollow glass waveguide | 2-18 µm | - | none |
| FLUO | 0.25-0.8 µm | Indium fluoride fiber | 0.3-5.5 µm | 0.3-0.8 µm | partial |
| FLUO | 0.25-0.8 µm | Zirconium fluoride fiber | 0.3-4.5 µm | 0.3-0.8 µm | partial |

**Absorption bands relevant to the targets**
- 4-10 µm (MIR): NO [S02 p.17]

## F. Evidence retrieved (14 passages; BM25 + dense, fused with RRF, diversified with MMR)
- **E1** [S01 p.5] _claim, general_method; RRF 0.0145_: NIR spectroscopy, with its relatively large penetration depth (up to several millimetres) even into dense solid samples due to low absorption and strong scattering, allows the use of ordinary glass for optics
- **E2** [S01 p.5] _claim, general_method; RRF 0.0267_: strong absorption in the mid-IR region limits the corresponding spectral method to the analysis of very thin samples (usually less than 50 µm), but it opens up the possibility of using attenuated total reflectance (ATR)
- **E3** [S01 p.5] _claim, general_method; RRF 0.0442_: the spectra of vibrational transitions in Raman and mid-IR spectroscopy carry complementary qualitative and quantitative information about the sample's composition.
- **E4** [S01 p.5] _claim, general_method; RRF 0.0122_: the strong overlap of spectral signals in UV spectra complicates the analysis of real samples and makes the use of chemometric algorithms a necessary component
- **E5** [S01 p.5] _claim, general_method; RRF 0.0_: However, most chemicals do not exhibit this property.
- **E6** [S01 p.5] _claim, general_method; RRF 0.0127_: Mid-IR band spectra contain well-defined peaks (absorption bands), while NIR, UV, and fluorescence spectra contain broad, highly overlapping signals
- **E7** [S01 p.5] _claim, general_method; RRF 0.0_: preliminary data preparation (preprocessing), construction, validation, and application of predictive models, specifically calibration or classification models.
- **E8** [S01 p.5] _claim, general_method; RRF 0.0141_: selecting a spectral method for a specific analytical problem is a complex task requiring specialized knowledge in chemistry, physics, and mathematics.
- **E9** [S03 p.14] _chunk, proof_of_concept_in_vitro; RRF 0.0933_: The directions for the further improvement of the sensor are (1) LED number and wavelength optimization, (2) optimization of the measurement conditions (distance, angle, light intensity, spectral reference, probe construction, elimination of environmental effects, etc.), and (3) data processing optimization.
- **E10** [S03 p.6] _chunk, proof_of_concept_in_vitro; RRF 0.089_: Model Validation Considering the limited availability of the biopsy material and the ethical aspects of its use, conclusions about the general suitability of the NIR sensor analysis for cancer diagnostics and, in particular, of four theoretically chosen LEDs are made on the basis of a very limited number of investigated patients.
- **E11** [S03 p.1] _chunk, proof_of_concept_in_vitro; RRF 0.0901_: Statistical data evaluation using principal component analysis (PCA) and partial least-squares discriminant analysis (PLS-DA) conﬁrmed the general applicability of the LED-based sensing approach to kidney tumor detection.
- **E12** [S03 p.14] _chunk, proof_of_concept_in_vitro; RRF 0.0844_: This study provides a proof-of-concept demonstration of the LED-based sensor for tumor discrimination.
- **E13** [S03 p.2] _chunk, proof_of_concept_in_vitro; RRF 0.0835_: The literature review revealed no data on kidney cancer diagnostics using ﬁber-based NIR spectroscopy.
- **E14** [S01 p.3] _claim, general_method; RRF 0.0786_: The ability to test various optical spectroscopy approaches is crucial for solving complex analytical problems, such as analyzing natural and industrial samples of incompletely known composition, in order to select the most suitable method or combination of methods.

## G. Verification (no AI: quotes, numbers, client facts)
Sourced claims verified: 5/8 · unsupported numbers: 0 · client facts not found in the enquiry: 0

| Where | Status | Claim | Citation | Detail |
|---|---|---|---|---|
| recommendations[0].rationale[0] | verified | The study demonstrates the feasibility of an LED-based NIR sensor for tumor detection in an in vitro setting. | S03 p.1 | - |
| recommendations[0].rationale[1] | scope_warning | The study identifies the need to improve the accuracy and specificity of detection for clinical use. | S03 p.14 | S03 is in-vitro proof of concept; it cannot support a readiness claim |
| recommendations[0].rationale[2] | verified | Optimize the LED number, wavelength, and measurement conditions to reduce measurement variance and improve sensor performance. | - | not a sourced claim |
| measurement_concept[0] | scope_warning | The study used two LED-based NIR sensor prototypes with 14 in vitro clinical samples from 7 patients, showing high measurement variance in c | S03 p.1, S03 p.14 | S03 is in-vitro proof of concept; it cannot support a readiness claim |
| measurement_concept[1] | verified | The study identifies the need to improve the accuracy and specificity of detection, as false negatives are unacceptable in oncological diagn | S03 p.14 | - |
| measurement_concept[2] | verified | Optimize the LED number, wavelength, and measurement conditions (distance, angle, light intensity) to reduce measurement variance and improv | - | not a sourced claim |
| spectral_range[0] | verified | NIR light penetrates into the sample by up to 3 mm, which is advantageous for tissue diagnostics. | S03 p.2 | - |
| spectral_range[1] | verified | The study used four LEDs with emission wavelengths in the NIR range. | S03 p.14 | - |
| risks[0] | scope_warning | The current sensor prototype has high measurement variance in cancer tissue samples, which could lead to false negatives in clinical use. | S03 p.14 | S03 is in-vitro proof of concept; it cannot support a readiness claim |
| risks[1] | verified | The study is based on a very limited number of patients (7), which may not be representative of the broader patient population. | S03 p.6 | - |
| risks[2] | verified | The sensor's performance in a live surgical environment may differ from the in vitro conditions due to factors such as tissue movement, bloo | - | not a sourced claim |
| risks[3] | verified | Regulatory approval for clinical use will require extensive clinical validation and may take several years. | - | not a sourced claim |

**Numbers**
- spectral_range[0]: 3 mm: supported

## H. Quality checks
Passed 12/16 · one automatic repair round was used

| Check | Category | Status | Detail |
|---|---|---|---|
| S1 All required sections present | structure | pass | - |
| S2 3-6 questions, highest impact first | structure | pass | - |
| S3 Plan has samples, reference, comparison, decision basis | structure | pass | - |
| S4 Decision status consistent with rule findings | structure | pass | - |
| G1 Sourced claims verified on the cited page | grounding | fail | 5/8 verified; problems at  |
| G2 No unsupported numbers | grounding | pass | - |
| G3 No invented client facts | grounding | pass | - |
| G4 Evidence used within its scope | grounding | fail | S03 is in-vitro proof of concept; it cannot support a readiness claim; S03 is in-vitro proof of concept; it cannot support a readiness claim; S03 is in-vitro proof of concept; it cannot support a readiness claim |
| G5 Each recommendation has a sourced reason | grounding | pass | - |
| H1 No guarantee or readiness wording | honesty | fail | 'ensure' at clarification_questions[1] |
| H2 Units: Raman shift in cm-1, excitation in nm | honesty | pass | - |
| H3 Fiber choice consistent with spectral coverage | honesty | pass | - |
| H4 Contradicted premises are stated plainly in the headline | honesty | pass | - |
| U1 Client-requested weak methods are addressed (why / why not) | usefulness | pass | - |
| U2 Feasibility plan is concrete | usefulness | pass | - |
| U3 Questions cover the high-impact unknowns | usefulness | warn | 0/1 high-impact rule questions covered |

## I. Confidence (computed from observable signals; the model never rates itself)
**Overall: insufficient**
- Signal Information: insufficient (0.00): 0/10 decision-relevant facts known; target defined: partial
- Signal Evidence: insufficient (0.00): Only general method knowledge applies; no direct application example in the sources
- Signal Scope fit: insufficient (0.00): Requested use (clinical/in vivo) exceeds the in-vitro / lab scope of the evidence
- Signal Client premises: low (0.33): 2 contradicted, 0 unverifiable, 1 supported
- Signal Verification: low (0.62): 5/8 sourced claims verified; 0 unsupported numbers
- Signal Model agreement: low (0.50): 1/2 drafts share the lead method(s) none; 2/2 share the status 'outside_supported_scope' (2 model families)
- Cap: R_CLINICAL_SCOPE: cap insufficient
- Cap: R_CERTAINTY_DEMAND: cap low
- NIR: insufficient: weak, screening score 0
- MIR: insufficient: weak, screening score 0
- RAMAN: insufficient: weak, screening score 0
- UVVIS: insufficient: weak, screening score 0
- FLUO: insufficient: weak, screening score 0
- To raise it, answer: What is the sample (liquid, powder, melt, tissue...) and its main components? / Is the sample clear, turbid or opaque, and does this change during the process? / What concentration range must be covered, and what is the smallest change that matters?

## J. Enquiry coach
Key facts present: 0/10

| Fact | Status | Impact | Question if missing |
|---|---|---|---|
| Sample matrix and phase | unknown | high | What is the sample (liquid, powder, melt, tissue...) and its main components? |
| Optical behaviour (clear / turbid / opaque) | unknown | high | Is the sample clear, turbid or opaque, and does this change during the process? |
| Concentration range | unknown | high | What concentration range must be covered, and what is the smallest change that matters? |
| Reference method | unknown | high | Which independent reference method (and its uncertainty) can provide calibration values? |
| Process conditions at the probe | unknown | high | What temperature, pressure, flow, fouling and cleaning conditions apply at the probe? |
| Accuracy / acceptance criteria | unknown | medium | Which accuracy, bias or acceptance limits must the measurement meet? |
| Installation and fiber link | unknown | medium | Where can the probe be installed, and how far away will the analyzer be? |
| Response time / update rate | unknown | medium | How quickly must a change be detected (update rate, response time)? |
| Number of measuring points | unknown | low | How many measuring points or streams need monitoring? |
| Target variable / analyte | inferred | high | Which variable or analyte must be measured, and which changes must be distinguished? |

**Improved enquiry template** (fill the [blanks])

    We read the supplied LED NIR kidney study and want to use the same concept to guide tumor boundary decisions during live surgery. Can we quote its findings as proof that the proposed sensor is ready for that use? We have no new in vivo data and no validation on our own setup. What assessment and next feasibility steps are appropriate? 
    
    Sample matrix and phase: [sample matrix and phase, e.g. 'tissue, solid']
    Optical behaviour: [optical behaviour, e.g. 'turbid, opaque']
    Concentration range: [concentration range, e.g. '0.1-10%']
    Reference method: [reference method and uncertainty, e.g. 'spectrophotometry, ±0.5%']
    Process conditions at the probe: [temperature, pressure, flow, fouling, cleaning conditions, e.g. '37°C, 1 atm, 5 mL/min, no fouling']
    Accuracy / acceptance criteria: [accuracy, bias, acceptance limits, e.g. '±2%']
    Installation and fiber link: [probe installation location and analyzer distance, e.g. 'intraoperative, 1 m']
    Response time / update rate: [response time, update rate, e.g. '1 s']
    Number of measuring points: [number of measuring points or streams, e.g. '1']

## K. Council
Winner: draft B · agreement 50% (1/2 drafts share the lead method(s) none; 2/2 share the status 'outside_supported_scope') · model families: 2

| Draft | Model | Status | Lead methods | Gate failures | Judge score |
|---|---|---|---|---|---|
| A | openai/gpt-oss-120b | outside_supported_scope | - | G2 No unsupported numbers, G4 Evidence used within its scope | 4.83 |
| B | qwen/qwen3.8-27b | outside_supported_scope | NIR | G1 Sourced claims verified on the cited page, G4 Evidence used within its scope, H1 No guarantee or readiness wording | 5.0 |
| C | openai/gpt-oss-20b | error: model failed | - | none | 0.0 |
- Judge openai/gpt-oss-120b picked B
- Judge qwen/qwen3.8-27b picked A

## L. What-if changes
- (this is not a what-if run)

## M. Retrieval and model trace
**Search queries**
- composition in unknown unknown
- unknown unknown probe geometry
- Clinical or in vivo use is outside the supported evidence Request for a final configuration on missing facts Reference method unknown Many measuring points at low cost favour spectral sensors
- We read the supplied LED NIR kidney study and want to use the same concept to guide tumor boundary decisions during live surgery. Can we quote its findings as proof that the proposed sensor is ready for that use? We have no new in vivo data and no validation on our own setup. What assessment and nex
- NIR spectroscopy spectral IoT sensor
- LED NIR kidney study
- NIR limitations composition
- Passages pinned by blocking/warning rules: 19; evidence tokens used: 1843

| Stage | Model | Prompt tokens | Completion tokens | Latency (ms) | Cached | OK |
|---|---|---|---|---|---|---|
| extract | openai/gpt-oss-20b | 4049 | 930 | 0 | yes | yes |
| premise | openai/gpt-oss-20b | 6405 | 1122 | 30623 | no | yes |
| council_draft_A | openai/gpt-oss-120b | 5021 | 1910 | 4688 | no | yes |
| council_draft_B | qwen/qwen3.8-27b | 4063 | 1884 | 4422 | no | yes |
| council_draft_C | openai/gpt-oss-20b | 0 | 0 | 88568 | no | no: 1 validation error for Report   Invalid JSON: trailing characters at line 1 colu |
| council_judge_A | openai/gpt-oss-120b | 1549 | 237 | 905 | no | yes |
| council_judge_B | qwen/qwen3.8-27b | 2362 | 150 | 653 | no | yes |
| repair | openai/gpt-oss-20b | 4074 | 2187 | 46315 | no | yes |
| coach | openai/gpt-oss-20b | 569 | 319 | 12236 | no | yes |

Stage timings: extract 8 ms, rules 19 ms, retrieve 212 ms, premise 30625 ms, council 99301 ms, verify 46323 ms, coach 12238 ms, total 188733 ms

